Do Directors Own Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares?

If you want to know who really controls Fulgent Genetics, Inc. (NASDAQ:FLGT), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.'

With a market capitalization of US$210m, Fulgent Genetics is a small cap stock, so it might not be well known by many institutional investors. In the chart below below, we can see that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about FLGT.

View our latest analysis for Fulgent Genetics

NasdaqGM:FLGT Ownership Summary, September 5th 2019
NasdaqGM:FLGT Ownership Summary, September 5th 2019
Advertisement

What Does The Institutional Ownership Tell Us About Fulgent Genetics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors own 19% of Fulgent Genetics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Fulgent Genetics, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqGM:FLGT Income Statement, September 5th 2019
NasdaqGM:FLGT Income Statement, September 5th 2019

Hedge funds don't have many shares in Fulgent Genetics. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Fulgent Genetics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own the majority of Fulgent Genetics, Inc.. This means they can collectively make decisions for the company. So they have a US$120m stake in this US$210m business. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.

General Public Ownership

The general public, with a 24% stake in the company, will not easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqGM:FLGT

Fulgent Genetics

Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

Adequate balance sheet with minimal risk.

Advertisement

Weekly Picks

CE
Ceazar
CNXU logo
Ceazar on Conexeu Sciences ·

This small biotech is developing technology that could potentially change how tissue is rebuilt

Fair Value:US$25.3447.6% undervalued
32 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
HE
HedgeY
PWR logo
HedgeY on Quanta Services ·

The Picks-and-Shovels Leader of the Grid Supercycle

Fair Value:US$7101.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
FU
KRMN logo
FundamentalFlow on Karman Holdings ·

KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Fair Value:US$105.652.3% undervalued
28 users have followed this narrative
2 users have commented on this narrative
13 users have liked this narrative
DO
Double_Bubbler
IES logo
Double_Bubbler on Invinity Energy Systems ·

Invinity Energy Systems: All About That BESS

Fair Value:UK£162.2% undervalued
38 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

RO
RockeTeller
AREC logo
RockeTeller on American Resources ·

American Resources, $263M Market Cap + 19% ReElement Stake, From Coal to Critical Minerals

Fair Value:US$557.0% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HU
EPB logo
Hunter_Z on EPB Group Berhad ·

EPB: Strong Shareholder Backing, Continuous Insider Buying and Growth Opportunities Ahead

Fair Value:RM 0.548.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YO
MS
youwakeup on Harvest Strategy Enhanced High Income Shares ETF ·

MSTE: Turning Bitcoin Volatility Into Monthly Cash Flow

Fair Value:CA$11.7579.4% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.1% undervalued
68 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9639.0% undervalued
58 users have followed this narrative
9 users have commented on this narrative
17 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1928.5% undervalued
52 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative